Liver metastases from colorectal cancer: Radioembolization with systemic therapy

Nature Reviews Clinical Oncology

Volumn 6, Issue 12, 2009, Pages 687-697

  Nicolay, Nils H ^a   Berry, David P ^b   Sharma, Ricky A ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b LEICESTER GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLOXURIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; LANSOPRAZOLE; OMEPRAZOLE; OXALIPLATIN; PROTON PUMP INHIBITOR; RADIOACTIVE MICROSPHERE; RADIOSENSITIZING AGENT; RESIN; VASCULOTROPIN INHIBITOR; ANTINEOPLASTIC AGENT; YTTRIUM;

ACUTE CHOLECYSTITIS; ADVANCED CANCER; BILE DUCT OBSTRUCTION; BILOMA; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SURGERY; CHEMOEMBOLIZATION; CHOLANGITIS; CLINICAL TRIAL; COLORECTAL CANCER; CONTINUOUS INFUSION; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; DRUG BINDING; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG TARGETING; ELECTIVE SURGERY; HEAD AND NECK CANCER; HEPATITIS; HUMAN; LIVER METASTASIS; MULTIPLE CYCLE TREATMENT; NECROSIS; NEUTROPENIA; NONHUMAN; PANCREATITIS; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; RADIOSENSITIZATION; RECTUM CANCER; REPEATED DRUG DOSE; REVIEW; SEPSIS; STOMACH ULCER; SURGICAL TECHNIQUE; SYSTEMIC THERAPY; TREATMENT DURATION; TREATMENT OUTCOME; ARTIFICIAL EMBOLISM; COLORECTAL TUMOR; LIVER TUMOR; METASTASIS; MULTIMODALITY CANCER THERAPY; PATHOLOGY;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; EMBOLIZATION, THERAPEUTIC; HUMANS; LIVER NEOPLASMS; YTTRIUM RADIOISOTOPES;

EID: 75649083860     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2009.165     Document Type: Review

References (83)

1. National Cancer Institute SEER Cancer Statistics Review, 1975-2005 [online], http://www.seer.cancer.gov/csr/1975-2006/ index.html (2008).
2. Goyle, S. & Maraveyas, A. Chemotherapy for colorectal cancer. Dig. Surg. 22, 401-414 (2005).
3. Giantonio, B. J. et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J. Clin. Oncol. 25, 1539-1544 (2007).
4. Nagorney, D. M. & Gigot, J. F. Primary epithelial hepatic malignancies: etiology, epidemiology, and outcome after subtotal and total hepatic resection. Surg. Oncol. Clin. N. Am. 5, 283-300 (1996).
5. Nordlinger, B. et al. Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group. Eur. J. Cancer 43, 2037-2045 (2007). (Pubitemid 47380368)
6. Hong, K., Georgiades, C. S. & Geschwind, J. F. Technology insight: image-guided therapies for hepatocellular carcinoma-intra-arterial and ablative techniques. Nat. Clin. Pract. Oncol. 3, 315-324 (2006). (Pubitemid 43871542)
7. 90Y microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium. Int. J. Radiat. Oncol. Biol. Phys. 68, 13-23 (2007).
8. Hamoudeh, M., Kamleh, M. A., Diab, R. & Fessi, H. Radionuclides delivery systems for nuclear imaging and radiotherapy of cancer. Adv. Drug Deliv. Rev. 60, 1329-1346 (2008).
9. Breedis, C. & Young, G. The blood supply of neoplasms In the liver. Am. J. Pathol. 30, 969-977 (1954).
10. 90Y microspheres in man: review of four explanted whole livers. Int. J. Radiat Oncol. Biol. Phys. 60, 1552-1563 (2004).
11. 90Y microsphere therapy. Phys. Med. Biol. 46, 487-498 (2001).
12. Sirtex Medical Annual Report [online], http://www.sirtex.com/files/ Sirtex-Annual-Repprt-2008.pdf (2009).
13. Gray, B. N., Burton, M. A., Kelleher, D. K., Anderson, J. & Klemp, P Selective internal radiation (SIR) therapy for treatment of liver metastases: measurement of response rate. J. Surg. Oncol. 42, 192-196 (1989). (Pubitemid 19285063)
14. 90Y microspheres. Aust. NZ J. Surg. 62, 105-110 (1992).
15. 90Yttrium microspheres for extensive colorectal liver metastases. Hepatogastroenterology 48, 333-337 (2001).
16. Gray, B. et al. Randomised trial of SIR-spheres plus chemotherapy vs chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. Ann. Oncol. 12, 1711-1720 (2001). (Pubitemid 34105661)
17. Van Hazel, G. et al. Randomised phase 2 trial of SIR-spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone In advanced colorectal cancer. J. Surg. Oncol. 88, 78-85 (2004). (Pubitemid 39536508)
18. Therasse, P et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl Cancer Inst. 92, 205-216 (2000).
19. 90Yttrium microspheres with concomitant systemic oxaliplatin, fluorouracil, and leucovorin chemotherapy. J. Clin. Oncol. 25, 1099-1106 (2007).
20. Goldberg, R. M. et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations In patients with previously untreated metastatic colorectal cancer. J. Clin. Oncol. 22, 23-30 (2004).
21. Van Hazel, G. et al. Treatment of fluourouracil-refractory patients with liver metastases from colorectal cancer by using yttrium-90 resin microspheres plus concomitant systemic irinotecan chemotherapy. J. Clin. Oncol. 27, 4089-4095 (2009).
22. Gulec, S. A. et al. A phase II clinical trial of yttrium-90 microspheres selective internal radiation treatment with concomitant chemotherapy as a front-line treatment in patients with colorectal cancer liver metastases: evaluation of objective tumor response by quantitative FDG-PET/CT imaging [abstract]. Ann. Surg. Oncol. 15 (Suppl. 2), a201 (2008).
23. 90yttrium resin microspheres alone in unresectable, chemotherapy refractory colorectal liver metastases: results of a phase II trial [abstract]. J. Clin. Oncol. 26 (Suppl.), a4078 (2008).
24. 90Y-microsphere brachytherapy for unresectable colorectal liver metastases: modern USA experience. Int. J. Radiat. Oncol. Biol. Phys. 65, 412-425 (2006).
25. Jakobs, T. F. et al. Hepatic yttrium-90 radioembolization of chemotherapy-refractory colorectal cancer liver metastases. J. Vasc. Interv. Radiol. 19, 1187-1195 (2008).
26. Vente, M. A. et al. Yttrium-90 microsphere radioembolization for the treatment of liver malignancies: a structured meta-analysis. Eur. Radiol. 19, 951-959 (2008).
27. Steel, G. G. Terminology in the description of drug-radiation interactions. Int. J. Radiat. Oncol. Biol. Phys. 5, 1145-1150 (1979).
28. de Gramont, A. et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment In advanced colorectal cancer. J. Clin. Oncol. 18, 2938-2947 (2000).
29. Longley, D. B., Harkin, D. P. & Johnston, P. G. 5-fluorouracil: mechanisms of action and clinical strategies. Nat. Rev. Cancer 3, 330-338 (2003).
30. Spiegelman, S. et al. Improving the anti-tumor activity of 5-fluorouracil by increasing its incorporation into RNA via metabolic modulation. Proc. Natl Acad. Sci. USA 77, 4966-4970 (1980). (Pubitemid 11236547)
31. Bruso, C. E., Shewach, D. S. & Lawrence, T. S. Fluorodeoxyuridine- induced radiosensitization and inhibition of DNA double strand break repair In human colon cancer cells. Int. J. Radiat. Oncol. Biol. Phys. 19, 1411-1417 (1990).
32. Yoshioka, A. et al. Deoxyribonucleoside triphosphate imbalance. 5-fluorodeoxyuridineinduced DNA double strand breaks in mouse FM3A cells and the mechanism of cell death. J. Biol. Chem. 262, 8235-8241 (1987).
33. Lawrence, T. S., Davis, M. A. & Maybaum, J. Dependence of 5-fluorouracil-mediated radiosensitization on DNA-directed effects. Int. J. Radiat. Oncol. Biol. Phys. 29, 519-523 (1994). (Pubitemid 24187920)
34. Schlemmer, H. P. et al. Alterations of intratumoral pharmacokinetics of 5-fluorouracil in head and neck carcinoma during simultaneous radiochemotherapy. Cancer Res. 59, 2363-2369 (1999).
35. Miwa, M. et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur. J. Cancer 34, 1274-1281 (1998). (Pubitemid 28342121)
36. Sawada, N., Ishikawa, T., Sekiguchi, F. Tanaka, Y. & Ishitsuka, H. X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts. Clin. Cancer Res. 5, 2948-2953 (1999). (Pubitemid 29493974)
37. Douillard, J. Y. et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355, 1041-1047 (2000).
38. Hsiang, Y. H., Hertzberg, R., Hecht, S. & Liu, L. F. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J. Biol. Chem. 260, 14873-14878 (1985). (Pubitemid 16211028)
39. Giovanella, B. C. et al. DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science 246, 1046-1048 (1989).
40. Pizzolato, J. F. & Saltz, L. B. The camptothecins. Lancet 361, 2235-2242 (2003).
41. Chen, A. Y., Chou, R., Shih, S. J., Lau, D. & Gandara, D. Enhancement of radiotherapy with DNA topoisomerase I-targeted drugs. Crit. Rev. Oncol. Hematol. 50, 111-119 (2004). (Pubitemid 38638738)
42. Li, T. K. & Liu, L. F. Tumor cell death induced by topoisomerase-targeting drugs. Annu. Rev. Pharmacol. Toxicol. 41, 53-77 (2001).
43. Chen, A. Y. et al. Silatecan DB-67 is a novel DNA topoisomerase I-targeted radiation sensitizer. Mol. Cancer Ther. 4, 317-324 (2005).
44. Chen, A. Y., Okunieff, P., Pommier, Y. & Mitchell, J. B. Mammalian DNA topoisomerase I mediates the enhancement of radiation cytotoxicity by camptothecin derivatives. Cancer Res. 57, 1529-1536 (1997). (Pubitemid 27175571)
45. Cividalli, A. et al. Radiosensitization by oxaliplatin In a mouse adenocarcinoma: influence of treatment schedule. int. J. Radiat. Oncol. Biol. Phys. 52, 1092-1098 (2002). (Pubitemid 34219031)
46. Kelland, L. The resurgence of platinum-based cancer chemotherapy. Nat. Rev. Cancer 7, 573-584 (2007).
47. Wu, B., Dröge, P. & Davey, C. A. Site selectivity of platinum anticancer therapeutics. Nat. Chem. Biol. 4, 110-112 (2008).
48. Espinosa, M. et al. Oxaliplatin activity in head and neck cancer cell lines. Cancer Chemother. Pharmacol. 55, 301-305 (2005). (Pubitemid 40142896)
49. Faivre, S., Chan, D., Salinas, R., Woynarowska, B. & Woynarowski, J. M. DNA strand breaks and apoptosis induced by oxaliplatin In cancer cells. Biochem. Pharmacol. 66, 225-237 (2003). (Pubitemid 36776396)
50. Koivusalo, R., Krausz, E., Ruotsalainen, P., Helenius, H. & Hietanen, S. Chemoradiation of cervical cancer cells: targeting human papillomavirus E6 and p53 leads to either augmented or attenuated apoptosis depending on the platinum carrier ligand. Cancer Res. 62, 7364-7371 (2002). (Pubitemid 36025260)
51. Prewett, M. C. et al. Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 In combination with irinotecan (CPT-11) against human colorectal tumor xenografts. Clin. Cancer Res. 8, 994-1003 (2002).
52. Dutta, P. R. & Maity, A. Cellular responses to EGFR inhibitors and their relevance to cancer therapy. Cancer Lett. 254, 165-177 (2007). (Pubitemid 47161103)
53. Yoshida, T., Okamoto, I., Iwasa, T., Fukuoka, M. & Nakagawa, K. The anti-EGFR monoclonal antibody blocks cisplatin-induced activation of EGFR signaling mediated by HB-EGF FEBS Lett. 582, 4125-4130(2008).
54. Bonner, J. A. et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 354, 567-578 (2006).
55. Huang, S. M., Bock, J. M. & Harari, P. M. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res. 59, 1935-1940 (1999).
56. Huang, S. M. & Harari, P. M. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin. Cancer Res. 6, 2166-2174 (2000).
57. Dittmann, K., Mayer, C. & Rodemann, H. P. Inhibition of radiation-induced EGFR nuclear import by C225 (cetuximab) suppresses DNA-PK activity. Radiother. Oncol. 76, 157-161 (2005). (Pubitemid 41725442)
58. Luwor, R. B. et al. The antiepidermal growth factor receptor monoclonal antibody cetuximab/ C225 reduces hypoxia-inducible factor-1 alpha, leading to transcriptional inhibition of vascular endothelial growth factor expression. Oncogene 24, 4433-4441 (2005).
59. Fukusato, T., Mori, S., Kawamoto, T., Taniguchi, S. & Machinami, R. Immunohistochemical and ultrastructural localization of epidermal growth factor receptor In human liver and hepatocellular carcinoma tissues. Acta Pathol. Jpn. 40, 22-29 (1990). (Pubitemid 20196844)
60. Baselga, J. et al. Phase I studies of antiepidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J. Clin. Oncol. 18, 904-914 (2000). (Pubitemid 30106623)
61. Ma, J. et al. Pharmacodynamic-mediated reduction of temozolomide tumor concentrations by the angiogenesis inhibitor TNP-470. Cancer Res. 61, 5491-5498 (2001). (Pubitemid 32694932)
62. Jain, R. K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307, 58-62 (2005).
63. Gorski, D. H. et al. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res. 59, 3374-3378 (1999).
64. Lee, C. G. et al. Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res. 60, 5565-5570 (2000).
65. Duda, D. G., Jain, R. K. & Willett, C. G. Antiangiogenics: the potential role of integrating this novel treatment modality with chemoradiation for solid cancers. J. Clin. Oncol. 25, 4033-4042 (2007).
66. Murthy, R. et al. Hepatic yttrium-90 radioembolotherapy in metastatic colorectal cancer treated with cetuximab or bevacizumab. J. Vase. interv. Radiol. 18, 1588-1591 (2007). (Pubitemid 350151878)
67. Riaz, A. et al. Complications following radioembolization with yttrium-90 microspheres: a comprehensive literature review. J. Vase. Interv. Radiol. 20, 1121-1130 (2009).
68. Atassi, B. et al. Biliary sequelae following radioembolization with yttrium-90 microspheres. J. Vase. Interv. Radiol. 19, 691-697 (2008).
69. Ng, S. S., Yu, S. C., Lai, P. B. & Lau, W. Y. Biliary complications associated with selective internal radiation (SIR) therapy for unresectable liver malignancies. Dig. Dis. Sci. 53, 2813-2817 (2008).
70. Van den Eynde, M. et al. Inducing resectability of chemotherapy refractory colorectal liver metastasis by radioembolization with yttrium-90 microspheres. Clin. Nucl. Med. 33, 697-699 (2008).
71. 90yttrium microspheres. Dig. Dis. Sci. 53, 2556-2563 (2008).
72. Vauthey, J. N. et al. Chemotherapy regimen predicts steatohepatltis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J. Clin. Oncol. 24, 2065-2072 (2006).
73. Lau, W. Yi et al. Salvage surgery following downstaging of unresectable hepatocellular carcinoma. Ann. Surg. 240, 299-305 (2004).
74. 90Yttrium microspheres. J. Clin. Oncol. 24, e15 (2006).
75. 90Yttrium microspheres: an unknown complication. J. Clin. Oncol. 23, 8275-8276 (2005).
76. Gillams, A. R. & Lees, W. R. Radiofrequency ablation of colorectal liver metastases. Abdom. Imaging 30, 419-426 (2005).
77. 90Yttrium microspheres in metastatic liver disease-Is it feasible? Eur. J. Radiol. doi:10.1016/j.ejrad.2009.02.001.
78. Stubbs, R. & Wickremesekera, S. Selective internal radiation therapy (SIRT): a new modality for treating patients with colorectal liver metastases. HPB (Oxford) 6, 133-139 (2004). (Pubitemid 39248172)
79. Tan, T. H., Kosmider, S., Yip, D. & Gibbs, P. Clinical experience of selective internal radiation therapy in combination with systemic chemotherapy as first-line therapy in patients with unresectable hepatic metastases from colorectal cancer [abstract]. J. Clin. Oncol. 26 (Suppl.), a15080 (2008).
80. Ruers, T. et al. Radiofrequency ablation (RFA) combined with chemotherapy for unresectable colorectal liver metastases (CRC LM): interim results of a randomised phase II study of the EORTC-NCRI CCSG-ALM Intergroup 40004 (CLOCC) [abstract]. J. Clin. Oncol. 26 (Suppl.), a4012 (2008).
81. Adam, R. et al. Patients with initially unresectable colorectal liver metastases: is there a possibility of cure? J. Clin. Oncol. 27, 1829-1835 (2009).
82. Dzik-Jurasz, A. et al. Diffusion MRI for prediction of response of rectal cancer to chemoradiation. Lancet 360, 307-308 (2002). (Pubitemid 34874724)
83. 18F-FDG PET scans after neoadjuvant chemoradiation provides prognostic stratification in patients with locally advanced rectal carcinoma subsequently treated by radical surgery. J. Nucl. Med. 47, 14-22 (2006).